StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Core structure exploration tiers

Rule-based Catalog Exploration Score from SMILES similarity, approved/clinical tags, family network size, and SAR metadata. It does not predict efficacy, safety, or development success.

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Core 후보 44파생 후보 15439 패밀리

MedMedium exploration priority3

Mid-pool Exploration Score (X-B bin)

High exploration priority2DStructureClassExploration ScoreFactors
Med
DM1
DM1 / maytansinoid payload family · Payload
Maytansinoid68패밀리 core · Payload core · SMILES 확보
Med
DM4
DM1 / maytansinoid payload family · Payload
Maytansinoid46Payload core · SMILES 확보
Med
SMCC-DM1
DM1 / maytansinoid payload family · Linker
Maytansinoid40Linker hub · SMILES 확보
MedDM1

DM1 / maytansinoid payload family · Payload · Maytansinoid

패밀리 core · Payload core · SMILES 확보

MedDM4

DM1 / maytansinoid payload family · Payload · Maytansinoid

Payload core · SMILES 확보

DM1 / maytansinoid payload family · Linker · Maytansinoid

Linker hub · SMILES 확보

Actual weights, formula and input limits

Exploration score method

StructureMoa ranks are a rule-based Exploration Score. An LLM does not predict activity or efficacy. Role, SMILES, and relation signals inside each family are summed and cut into High / Medium / Low exploration priority.

Core tab

  • scaffold / payload / linker role weights
  • family center-compound bonus
  • SMILES source (db · known · pubchem · inherited)
  • relation-edge count and derived-child count

Derivative tab

  • drug / derivative / adc candidates
  • similarity to family center via Morgan fingerprint, radius 2, 2048 bits, Tanimoto
  • Approval, clinical and lead tag bonuses have been removed.

Explore tab

  • sparse SAR, cross-scaffold pairs, expansion leaves
  • weakly linked nodes and catalog-coverage gaps
  • relation graph + stored Morgan fingerprints
  • category filters

Exploration-priority bins

  • High (X-S): top ~12%
  • Medium (X-A/X-B): ~12–62%
  • Low (X-C): remainder (pools under 5 compounds stay Medium)

Internal exploration metric based on catalog and structural signals. Not a prediction of efficacy, safety, potency, or development success.

Full methodology

평가 시각: 2026. 10. 29. 오전 12:24:23 · 캐시 5분 · 전체 패밀리